• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Shattuck Labs Inc.

    11/13/25 7:38:44 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Shattuck Labs, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    82024L103

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    82024L103


    1Names of Reporting Persons

    Prosight Management, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,543,240.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,543,240.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,543,240.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (i) 4,325,185 shares of common stock, $0.0001 par value per share ("Common Stock") of Shattuck Labs, Inc. (the "Issuer") owned by the Reporting Persons; and (ii) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days, subject to the Beneficial Ownership Limitation (as defined hereafter), upon the exercise of certain pre-funded warrants and common warrants (the "Warrants") held by the Reporting Persons. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder may not exercise any Warrants, to the extent that after giving effect to such issuance after exercise, the aggregate number of shares of Common Stock then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation"). The figure in Item 11 is based upon (i) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days upon the conversion of the Warrants up to the Beneficial Ownership Limitation; and (ii) 63,279,843 shares of Common Stock outstanding as of October 23, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 6, 2025.


    SCHEDULE 13G

    CUSIP No.
    82024L103


    1Names of Reporting Persons

    Prosight Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    600,310.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    600,310.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    600,310.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (i) 398,022 shares of Common Stock of the Issuer owned by Prosight Fund; and (ii) 202,288 shares of Common Stock that may be acquired by Prosight Fund within 60 days, subject to the Beneficial Ownership Limitation, upon the exercise of the Warrants held by the Prosight Fund. The figure in Item 11 is based upon (i) 202,288 shares of Common Stock that may be acquired by the Reporting Persons within 60 days upon the conversion of the Warrants up to the Beneficial Ownership Limitation; and (ii) 63,279,843 shares of Common Stock outstanding as of October 23, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 6, 2025.


    SCHEDULE 13G

    CUSIP No.
    82024L103


    1Names of Reporting Persons

    Prosight Plus Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,127,182.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,127,182.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,127,182.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (i) 1,192,668 shares of Common Stock of the Issuer owned by Prosight Plus Fund; and (ii) 1,934,514 shares of Common Stock that may be acquired by Prosight Plus Fund within 60 days, subject to the Beneficial Ownership Limitation, upon the exercise of the Warrants held by the Prosight Plus Fund. The figure in Item 11 is based upon (i) 1,934,514 shares of Common Stock that may be acquired by the Reporting Persons within 60 days upon the conversion of the Warrants up to the Beneficial Ownership Limitation; and (ii) 63,279,843 shares of Common Stock outstanding as of October 23, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 6, 2025.


    SCHEDULE 13G

    CUSIP No.
    82024L103


    1Names of Reporting Persons

    Prosight Partners, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,543,240.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,543,240.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,543,240.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (i) 4,325,185 shares of Common Stock of the Issuer owned by the Reporting Persons; and (ii) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days, subject to the Beneficial Ownership Limitation, upon the exercise of the Warrants held by the Reporting Persons. The figure in Item 11 is based upon (i) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days upon the conversion of the Warrants up to the Beneficial Ownership Limitation; and (ii) 63,279,843 shares of Common Stock outstanding as of October 23, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 6, 2025.


    SCHEDULE 13G

    CUSIP No.
    82024L103


    1Names of Reporting Persons

    W. Lawrence Hawkins
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,543,240.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,543,240.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,543,240.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (i) 4,325,185 shares of Common Stock of the Issuer owned by the Reporting Persons; and (ii) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days, subject to the Beneficial Ownership Limitation, upon the exercise of the Warrants held by the Reporting Persons. The figure in Item 11 is based upon (i) 2,218,055 shares of Common Stock that may be acquired by the Reporting Persons within 60 days upon the conversion of the Warrants up to the Beneficial Ownership Limitation; and (ii) 63,279,843 shares of Common Stock outstanding as of October 23, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 6, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Shattuck Labs, Inc.
    (b)Address of issuer's principal executive offices:

    500 W. 5th Street, Suite 1200 Austin, TX, 78701
    Item 2. 
    (a)Name of person filing:

    This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership ("Prosight Management"), Prosight Fund, LP, a Delaware limited partnership ("Prosight Fund"), Prosight Plus Fund, LP, a Delaware limited partnership ("Prosight Plus Fund"), Prosight Partners, LLC, a Delaware limited liability company ("Prosight Partners"), and W. Lawrence Hawkins (collectively referred to herein as "Reporting Persons"). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the "Managed Accounts") and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners. Prosight Fund, Prosight Plus Fund, and the Managed Accounts are the record and direct beneficial owner of the shares of Common Stock of the Issuer covered by this statement. Prosight Fund disclaims beneficial ownership of the shares of Common Stock of the Issuer held by each of the Managed Accounts, and Prosight Plus Fund. Prosight Plus Fund disclaims beneficial ownership of the shares of Common Stock of the Issuer held by each of the Managed Accounts, and Prosight Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    82024L103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 on the cover pages hereto.
    (b)Percent of class:

    See Item 11 on the cover pages hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover pages hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover pages hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover pages hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover pages hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Prosight Management, LP
     
    Signature:Prosight Partners, LLC
    Name/Title:General Partner
    Date:11/13/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner
    Date:11/13/2025
     
    Prosight Fund, LP
     
    Signature:Prosight Management, LP
    Name/Title:General Partner
    Date:11/13/2025
     
    Signature:Prosight Partners, LLC
    Name/Title:Sole Manager of the General Partner
    Date:11/13/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner of the General Partner
    Date:11/13/2025
     
    Prosight Plus Fund, LP
     
    Signature:Prosight Management, LP
    Name/Title:General Partner
    Date:11/13/2025
     
    Signature:Prosight Partners, LLC
    Name/Title:General Partner of the General Partner
    Date:11/13/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner of the General Partner
    Date:11/13/2025
     
    Prosight Partners, LLC
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager
    Date:11/13/2025
     
    W. Lawrence Hawkins
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:W. Lawrence Hawkins
    Date:11/13/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 29, 2023, by the Reporting Persons with the SEC).

    Get the next $STTK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    9/8/2025$4.00Outperform
    Wedbush
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    10/1/2024Buy → Neutral
    H.C. Wainwright
    6/17/2024Buy → Neutral
    BTIG Research
    8/31/2022$12.00Buy
    BTIG Research
    6/1/2022$13.00Buy
    Citigroup
    More analyst ratings

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    12/6/24 9:00:15 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Orbimed Advisors Llc

    3 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:48:37 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Shattuck Labs Inc.

    SCHEDULE 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/13/25 7:38:44 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K/A - Shattuck Labs, Inc. (0001680367) (Filer)

    11/6/25 5:15:49 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shattuck Labs Inc.

    10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

    11/6/25 4:34:01 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shattuck Labs to Participate in Upcoming December Investor Conferences

    AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th Annual Healthcare ConferenceFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerPresentation Date: Dec 2, 2025Time: 10:10 AM ESTL

    11/20/25 8:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    –First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025 and provided re

    11/6/25 4:30:00 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

    AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be moderated by covering analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., and will feature KOL Marla Dubinsky, M.D., Director of the Susan and Leonard Feinstein Inflammatory Bowel

    10/2/25 7:51:58 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Shattuck Labs with a new price target

    Wedbush initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

    9/8/25 8:58:49 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Shattuck Labs with a new price target

    Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

    3/17/25 7:44:03 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs downgraded by Citigroup with a new price target

    Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously

    10/2/24 7:58:39 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    View All

    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

    3/4/24 7:00:00 AM ET
    $IMNM
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

    11/6/23 9:28:40 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Changes to its Board of Directors

    AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

    10/28/21 4:30:00 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Financials

    Live finance-specific insights

    View All

    Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

    – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

    10/1/24 6:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

    6/14/24 6:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

    6/6/24 7:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/13/24 8:30:26 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/12/24 5:01:20 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care